Intelligence Profile
Research Papers
The available research on Pancragen consists primarily of laboratory and animal studies, with no clinical trials in humans identified. The compound appears to be a tetrapeptide (Lys-Glu-Asp-Trp-NH2) that has been studied mainly in aging-related pancreatic function.
Animal Studies
The most substantial research comes from studies in aging rhesus monkeys. A 2015 study examined Pancragen's effects on glucose tolerance in old female rhesus monkeys, while a 2014 study investigated its impact on pancreatic endocrine function in the same species. However, specific sample sizes and detailed methodologies are not available from the retrieved abstracts.
Laboratory Research
Several studies between 2007-2013 examined Pancragen's effects on pancreatic cell function and differentiation during aging. A 2013 study published in the Bulletin of Experimental Biology and Medicine investigated the compound's effects on pancreatic cell differentiation, while earlier work in 2012 looked at its tissue-specific stimulation of cell differentiation during aging.
Research from 2007 examined Pancragen's effects in rats with experimental diabetes, measuring blood glucose levels, capillary permeability, and adhesion. A 2010 study characterized the biological activity of the tetrapeptide itself.
Research Limitations
The evidence base is notably limited. All identified studies appear to be preclinical, conducted primarily in laboratory animals or cell cultures. No human clinical trials were found in the literature search. Most of the research appears to originate from Russian scientific publications, and detailed study parameters like sample sizes, control groups, and statistical methods are not available from the abstracts alone.
The research suggests potential effects on pancreatic function and glucose metabolism in aging, but the lack of human clinical data significantly limits any conclusions about therapeutic applications in people.